Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We evaluated the influence of some morphological changes of the NCI-H125 cell line in surface expression of the epidermal growth factor receptor (EGFR) and their impact on some biological activity assays using this molecule as target. Hematoxylin and eosin (H/E) staining, light microscopy immunocytochemistry, flow cytometric antibody-receptor binding test, cell viability determination and cell cycle analysis were performed. Phenotypic changes and inconsistency in EGFR expression were detected in NCI-H125 cell cultures. A significant reduction in the growth rate, mainly characterized by cell cycle arrest in the G0-G1 phase, was also evidenced. Differential distribution of cell viability in NCI-H125 subpopulations and its relationship with the EGFR surface expression were determined. Nuclear alterations observed in NCI- -H125 were not apoptosis related. A lack of control of cell cultures affects the reliability and reproducibility of biomedical and biotechnological research using EGFR as target. Therefore, rigorous control of the above mentioned parameters in these experiments is recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2478/v10007-012-0038-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Connexin43 Suppresses Lung Cancer Stem Cells.
Cancers (Basel)
February 2019
Department of Cancer Biology, University of Toledo Health Science Center, Toledo, OH 43614, USA.
Alterations in gap junctions and their protein components, connexins, have been associated with neoplastic transformation and drug resistance, and more recently have been shown to play important roles in cancer stem cells (CSCs). However, there is less knowledge of connexins and gap junctions in lung CSCs. To address this, Connexin43 (Cx43), the major human lung epithelial gap junction protein, was expressed ectopically in poorly expressing National Cancer Institute-125 (NCI-H125) metastatic human lung adenocarcinoma cells, and phenotypic characteristics of malignant cells and abundance of CSCs were evaluated.
View Article and Find Full Text PDFExpression of SIRT1 gene in human lung cancer lines enhances their sensitivity to the anticancer effects of cisplatin.
Eur Rev Med Pharmacol Sci
July 2018
Department of Clinical Laboratory, The First People's Hospital of Chongqing, Liang Jiang New Area, Chongqing, China.
Objective: Lung cancer is one of the lethal cancers and one of the major causes of cancer-related mortalities across the globe. SIRT1 gene has been reported to be involved in the progression and tumorigenesis of several types of cancers. However, the role of SIRT1 gene is in the progression of lung cancer is poorly understood.
View Article and Find Full Text PDFThe synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
Cancer Cell Int
March 2017
Universidad de Buenos Aires, Instituto de Oncología "Ángel H. Roffo", Área Investigaciones, Av. San Martín 5481, Buenos Aires, Argentina.
Background: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths worldwide. Up to 80% of cancer patients are classified as non-small-cell lung cancer (NSCLC) and cisplatin remains as the gold standard chemotherapy treatment, despite its limited efficacy due to both intrinsic and acquired resistance. The CK2 is a Ser/Thr kinase overexpressed in various types of cancer, including lung cancer.
View Article and Find Full Text PDFPhenotypic heterogeneity in the NCI-H125 cell line affects biological activity using the epidermal growth factor receptor as target.
Acta Pharm
December 2012
Laboratory of Specific Recognition and Biological Activity Assays, Department of Quality Control, Center of Molecular Immunology, Havana, Cuba.
We evaluated the influence of some morphological changes of the NCI-H125 cell line in surface expression of the epidermal growth factor receptor (EGFR) and their impact on some biological activity assays using this molecule as target. Hematoxylin and eosin (H/E) staining, light microscopy immunocytochemistry, flow cytometric antibody-receptor binding test, cell viability determination and cell cycle analysis were performed. Phenotypic changes and inconsistency in EGFR expression were detected in NCI-H125 cell cultures.
View Article and Find Full Text PDFImmunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy.
J Biomark
August 2015
Laboratory of Recognition and Biological Activity Assays, Department of Quality Control, Center of Molecular Immunology, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba.
Adequate methods to identify which lung cancer patients are most likely to benefit from the targeted drugs against both epidermal growth factor receptor/epidermal growth factor (EGFR/EGF) are needed. For this reason, we evaluated both the tissue reactivity of ior egf/r3 monoclonal antibody (Mab) in human lung carcinomas and its biological activity in NCI-H125 cells. Additionally, we assessed the tissue expression of EGF using two Mabs, CB-EGF1 and CB-EGF2.
View Article and Find Full Text PDF